Come up with a name for your new list and we'll add to it:
Zyngenia raised a round of funding on November 17, 2009. Investors include
New Enterprise Associates.
Zyngenia is a biotherapeutics company focused on the development of the next-generation of antibody-derived drugs. The company enables the development of singular molecular entities that address two …